Is Eprosartan + Hydrochlorothiazide registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Eprosartan + Hydrochlorothiazide, including TEVETEN PLUS 600-12.5MG FILM COATED TAB. (12.5,600 mg,mg, Film-coated tablet, SAR 76.50).

Is Eprosartan + Hydrochlorothiazide approved by the US FDA?

Drugs@FDA lists 1 application product line for Eprosartan + Hydrochlorothiazide, including TEVETEN HCT (Discontinued).

Active substances

Eprosartan + Hydrochlorothiazide

SFDA 1
US FDA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
TEVETEN PLUS 600-12.5MG FILM COATED TAB.	12.5,600 mg,mg	Film-coated tablet · Oral use	28 Blister	SAR 76.50	NCE · Prescription	Abbott Laboratories GmbH	Valid

Indications — CHI Daman Drug Formulary

HYPERTENSION

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
TEVETEN HCT	600MG;12.5MG; 600MG;25MG	tablet · oral	ABBVIE	Discontinued	1 Nov 2001

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.